Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial

T. Susanna Meijer*, Mark C. Burgmans, Marta Fiocco, Lioe Fee de Geus-Oei, Ellen Kapiteijn, Eleonora M. de Leede, Christian H. Martini, Rutger W. van der Meer, Fred G.J. Tijl, Alexander L. Vahrmeijer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)
43 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial'. Together they form a unique fingerprint.

Medicine and Dentistry